Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

A new review reports that nine people taking semaglutide and tirzepatide — the active ingredient in GLP-1 medications — ...

CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

Researchers looked at the nine people who had vision problems while using the drugs and is one of several that have ...

Reports link GLP-1 medications like Ozempic and Mounjaro to vision loss, prompting concerns over their safety.

A small number of patients using GLP-1 weight loss medications have experienced vision loss, although researchers have not ...

A small percentage have had vision problems, but a direct causal link with the drugs has not been established.

Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of ...

A recent study found that over a third of websites selling compounded diabetes and weight loss medications, such as Ozempic and Wegovy, falsely claim they are FDA-approved.

Boone Health is closing its bariatric clinic in Columbia because of lagging demand. "We're working to expand the high-demand ...

WVU Medicine is playing a lead role in a national clinical study of a minimally invasive surgical procedure for people who've ...

Obesity is an epidemic in the United States, but more people are shedding pounds with the help of weight loss drugs.